Regional Citrate vs. Systemic Unfractionated Heparin Anticoagulation for Continuous Renal Replacement Therapy in
Yi Wang1, Lan Yang1, Yaping Liu1
1Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Insights
Regional citrate anticoagulation (RCA) is superior to unfractionated heparin (UFH) for continuous renal replacement therapy in children. RCA prolonged circuit survival and reduced clotting and bleeding risks, making it a preferred choice, especially for infants.
Area of Science:
- Pediatric Nephrology
- Critical Care Medicine
- Pharmacology
Background:
- Continuous renal replacement therapy (CRRT) requires effective anticoagulation in pediatric patients.
- Unfractionated heparin (UFH) and regional citrate anticoagulation (RCA) are common methods, but their comparative efficacy and safety in children remain debated.
Purpose of the Study:
- To compare the efficacy and safety of RCA versus UFH for anticoagulation in pediatric patients undergoing CRRT.
- To identify the optimal anticoagulation strategy for different pediatric subgroups.
Main Methods:
- A systematic review and meta-analysis of studies from PubMed, Embase, and Cochrane Library databases (inception to 2024).
- Quality assessment using the Newcastle-Ottawa Scale.
- Sensitivity analysis and Egger's test for publication bias were performed.
Main Results:
- RCA significantly prolonged circuit survival time (WMD 12.09, p=0.002) and reduced filter clotting (RR=0.60, p=0.004) and bleeding risks (RR=0.42, p=0.007) compared to UFH.
- While RCA increased the risk of metabolic alkalosis (RR=3.22, p=0.009) and hypocalcemia (RR=2.92, p<0.001), these were manageable.
- RCA significantly extended circuit survival in children weighing ≤10 kg (p<0.001).
Conclusions:
- RCA is a more effective and safer anticoagulation strategy than UFH in pediatric CRRT.
- RCA is particularly beneficial for infants and children weighing ≤10 kg.
- RCA should be considered the first-choice anticoagulation method in pediatric CRRT.
Abstract:
The efficacy and safety of unfractionated heparin (UFH) and regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) are subjects of controversy across paediatric patients. We conducted a search of the PubMed, Embase and Cochrane Library databases from inception to 2024. The Newcastle-Ottawa Scale was used to assess the quality of the included studies. Sensitivity analysis confirmed the stability of results; publication bias was investigated by Egger test. We conducted a search of the PubMed, Embase and Cochrane Library databases from inception to 2024, and 12 studies were included. Compared with UFH, RCA significantly prolonged circuit survival time (WMD 12.09, 95% CI: [4.48, 19.71], p = 0.002), reduced the risk of filter clotting (RR = 0.60, 95% CI: [0.42-0.85], p = 0.004) and bleeding (RR = 0.42, 95% CI: [0.23-0.79], p = 0.007). Although citrate anticoagulation was more likely to cause metabolic alkalosis (RR = 3.22, 95% CI: [1.34-7.75], p = 0.009) and hypocalcemia (RR = 2.92, 95% CI: [1.93-4.41], p < 0.001), metabolic complications were manageable and mild. Further subgroup analysis of paediatrics showed that, compared with children with an average weight > 10 kg, citrate anticoagulation significantly extended the circuit survival time of children with an average weight ≤ 10 kg (p < 0.001). Sensitivity analysis confirmed that the results were generally robust. RCA could be the first choice for anticoagulation in paediatrics, especially for infants weighing ≤ 10 kg.
Related Concept Videos
Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cardiac Catheterization I: Pre-Procedure Overview


